In a significant leap forward for cardiac electrophysiology, Argá Medtech has announced the successful completion of patient enrollment for the paroxysmal atrial fibrillation (PAF) cohort of its pivotal COHERENT-AF (NCT06784466) trial. This milestone marks a critical juncture for the company’s proprietary Coherent Sine Burst Electroporation (CSE) platform, a next-generation pulsed-field ablation (PFA) system designed to treat symptomatic, drug-refractory atrial arrhythmias with unprecedented precision.
The accomplishment brings Argá Medtech closer to its goal of securing regulatory approvals in both the United States and Europe, signaling a potential paradigm shift in how cardiologists approach the treatment of complex heart rhythm disorders.
The Core Objective: Advancing Cardiac Ablation
Atrial fibrillation (AF) remains one of the most common and challenging cardiac arrhythmias, often requiring invasive intervention when pharmacological treatments fail to restore a healthy sinus rhythm. Current standards of care, such as thermal ablation (radiofrequency or cryoablation), have been effective but carry inherent risks of collateral tissue damage due to their reliance on extreme temperature changes.
The COHERENT-AF study is designed to rigorously evaluate the safety and effectiveness of Argá Medtech’s PFA system. Unlike thermal methods, PFA utilizes non-thermal, high-voltage electrical fields to create micro-scale perforations in the membranes of targeted cardiac cells—a process known as irreversible electroporation. This technique offers the distinct advantage of "tissue selectivity," meaning it can destroy arrhythmia-inducing tissue while leaving surrounding structures, such as the esophagus or phrenic nerve, unharmed.
The trial protocol is comprehensive, requiring all participants to undergo pulmonary vein isolation (PVI), the gold standard for AF treatment. Furthermore, the study grants physicians the flexibility to ablate additional cardiac targets, including the cavo-tricuspid isthmus, left atrial substrate, and the posterior wall, mirroring real-world clinical practice.
Chronology of the COHERENT-AF Trial
The journey toward this enrollment milestone has been marked by rapid execution and international collaboration.
- Initial Design and IDE Approval: Argá Medtech received Investigational Device Exemption (IDE) approval to commence the pivotal study, focusing on a multi-center approach spanning both European and American healthcare landscapes.
- Expansion of Clinical Sites: To ensure a robust data set, the company activated 27 medical centers across the US and Europe. These sites were carefully selected for their expertise in electrophysiology and their ability to handle complex patient populations.
- The PAF Enrollment Phase: The paroxysmal AF cohort, which involves patients experiencing intermittent but frequent episodes of AF, required the recruitment of 150 participants. This goal was achieved with notable speed, demonstrating high investigator engagement and patient demand for more advanced, non-thermal treatment options.
- The Current Phase: With the PAF arm concluded, the study is now transitioning its focus to the persistent AF cohort. The company anticipates completing the enrollment of the remaining 150 persistent AF participants within the next two months, moving the total study population toward its 410-patient capacity.
Supporting Data and Technological Innovation
The efficacy of the CSE platform rests on its sophisticated engineering. The system is comprised of two primary components: the SineBurst Ablation Catheter and the SineWave Ablation Generator.
Versatility in Design
One of the platform’s most lauded features is its operational simplicity. The catheter is configured via a straightforward stylet exchange, which minimizes procedural complexity. This allows electrophysiologists to deliver three distinct types of lesions—circular, focal, and linear—using a single device. Such versatility is crucial, as cardiac anatomy varies significantly from patient to patient.
Energy Delivery Mechanisms
The SineWave Ablation Generator is capable of emitting controlled microsecond bursts through two, four, or eight electrodes. The energy is intelligently titrated to match the requirements of the tissue being treated. For instance, the system can adjust its output to effectively ablate thin atrial walls while maintaining the power density required for thicker septal circuits. This adaptability is the hallmark of the "Sine Burst" technology, designed to optimize the balance between lesion depth and procedural safety.
Study Methodology
The study’s design is rigorous. Each participant is monitored over a 12-month follow-up period. Safety and effectiveness targets are measured separately for each cohort (paroxysmal vs. persistent), ensuring that the data provided to the FDA and European regulatory bodies is granular and statistically significant. By tracking patients for a full year, the trial intends to provide long-term evidence of the durability of the lesions created by the CSE platform.

Official Responses and Strategic Outlook
The leadership at Argá Medtech views the completion of the PAF cohort as a validation of both their technology and their clinical strategy.
"Reaching full enrollment so quickly in the paroxysmal AF cohort reflects the commitment of our investigators and study teams," said David Neale, CEO of Argá Medtech. "We are now focused on completing the persistent AF cohort and generating the evidence needed to support FDA and CE-Mark regulatory submissions of the CSE Platform."
The company, which operates out of the Biopôle Lausanne in Switzerland and maintains a secondary hub in San Diego, California, is well-positioned for the final push toward commercialization. With financial backing from a high-profile investment syndicate—including Advent Life Sciences, Earlybird, Gilde Healthcare, High-Tech Gründerfonds, and MedFocus—Argá Medtech possesses the capital and institutional support necessary to navigate the complexities of the late-stage regulatory process.
Implications for the Future of Cardiology
The implications of the COHERENT-AF study extend far beyond the immediate success of the enrollment phase.
A New Standard of Safety
If the final 12-month data confirms the safety profiles observed in early-stage testing, PFA could replace thermal ablation as the primary choice for cardiologists. The non-thermal nature of the procedure significantly reduces the risk of long-term complications, such as esophageal fistulas, which remain a rare but feared risk in traditional ablation.
Efficiency in the Cath Lab
The ability to perform multiple lesion types with a single catheter, as demonstrated by the Argá system, offers the potential to shorten procedural times. In a healthcare environment focused on maximizing throughput and reducing hospital stays, a faster, more effective procedure represents a major financial and operational gain for hospitals.
Competitive Landscape
The field of PFA is currently witnessing intense innovation, with several major medical device players racing to secure market share. Argá Medtech, however, differentiates itself through its proprietary "SineBurst" energy delivery. By focusing on the ability to treat both thin and thick cardiac tissue with the same platform, they are positioning themselves to address the most difficult-to-treat persistent AF cases, which have historically been resistant to standard ablation techniques.
Conclusion: The Path Ahead
As Argá Medtech moves into the final phase of the COHERENT-AF trial, the medical community will be watching closely. The completion of the persistent AF cohort will provide the definitive evidence required for regulatory clearance. If the results continue to mirror the success of the paroxysmal cohort, the CSE platform is poised to become a staple in electrophysiology labs worldwide.
The convergence of cutting-edge technology, strategic clinical site selection, and robust venture capital backing has placed Argá Medtech in an enviable position. By streamlining the procedural experience for both the physician and the patient, the company is not merely testing a new device—it is helping to redefine the gold standard of care for millions suffering from atrial arrhythmias.
The coming months, as the remaining participants complete their follow-up, will be pivotal in determining the future trajectory of the CSE platform and its role in the global fight against heart rhythm disease.
